|
BioScreening - organic compounds for screening
Clinical Trials NewsDiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs - BIRMINGHAM, Ala.–(BUSINESS WIRE)–DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the [...]
Clinical Trials in Asia Summit 2009 - st1\:* { BEHAVIOR: url(#ieooui) } @font-face { font-family: Verdana; } @page Section1 {size: 612.0pt 792.0pt; margin: 72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin: 35.4pt; mso-footer-margin: 35.4pt; mso-paper-source: 0; } P.MsoNormal { FONT-SIZE: 12pt; MARGIN: 0cm 0cm 0pt; FONT-FAMILY: “Times New Roman”; mso-style-parent: “”; mso-pagination: widow-orphan; mso-fareast-font-family: “Times New Roman” } LI.MsoNormal { FONT-SIZE: 12pt; MARGIN: 0cm 0cm [...]
Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs - BERKELEY, Calif.–(BUSINESS WIRE)–Plexxikon Inc. today announced the issuance of key composition-of-matter patents covering novel compounds discovered through the company’s Scaffold-Based Drug Discoveryâ„¢ platform. Plexxikon’s pipeline of preclinical and clinical stage product opportunities currently span [...]
GTCbio Announces 4th Annual Assay Development and Screening Conference taking place June 8-9, 2009. - San Francisco, CA - GTCbio Announces its 4th Annual Assay Development and Screening Conference taking place June 8-9, 2009. As compounds derived from high throughput screening increasingly find their way into clinical trials, drug screening has become widely accepted as a critical step in the drug discovery process. After more than a decade of rapid [...]
EPA Presents Initial Results from Caliper Life Sciences’ ToxCast Screening Effort - HOPKINTON, Mass., March 19 /PRNewswire-FirstCall/ — Caliper Life Sciences, Inc. (NASDAQ: CALP) , a leading provider of tools and services for drug discovery and life sciences research, today announced that the United States Environmental Protection Agency (EPA) presented initial analyses of Phase I data generated by Caliper Discovery Alliances and Services (CDAS) under the EPA’s [...]
Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs - BERKELEY, Calif.–(BUSINESS WIRE)–Plexxikon Inc. today announced the issuance of key composition-of-matter patents covering novel compounds discovered through the company’s Scaffold-Based Drug Discoveryâ„¢ platform. Plexxikon’s pipeline of preclinical and clinical stage product opportunities currently span [...]
International symposium “Stem Cell Transplantation in Multiple Sclerosis, October 5th, 2009 Moscow, Russia - International symposium “Stem Cell Transplantation in Multiple Sclerosis: Sharing the Experience” will be held on October 5th, 2009 in Moscow, Russia. Symposuim Organizers are Pirogov National Medical Surgical Center, National Center for Research and Treatment of Autoimmune Diseases, Russian Cooperative Group for Cellular Therapy, New Jersey Center for Quality of Life and Health Outcomes Research.
The [...]
CytRx Unveils Clinical Development Plan for Pipeline Assets - Names World-Renowned Cancer Drug Expert Dr. Joseph Rubinfeld as Chief Scientific Advisor
LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug [...]
MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease
The difficulties of Cushing’s syndrome
Tepnel Expands Genetic Services Portfolio with Addition of Illumina iScan Rapid Reader - MANCHESTER, United Kingdom & STAMFORD, Conn.–Tepnel Life Sciences PLC (AIM:
TED) today announced that it has expanded its molecular genetic services
offering through the addition of Illumina’s iScan System, a next-generation
scanner that provides researchers conducting genetic variation studies with
significantly greater throughput and application diversity. This
announcement marks the first anniversary of Tepnel’s new pharmaceutical
services facility and makes Tepnel [...]
Seegene/Lab901 brings a New Detection Platform for Multiple Pathogens to European Hospitals - Rockville, MD, and Edinburgh, Scotland, June 17, 2008:Â Seegene and Lab901 today announced the availability of a novel automated multi-pathogen walk-away detection platform for European hospitals. Based on the Seeplex(R) multiplexing PCR system and ScreenTape(R)Â gel electrophoresis detection system, this new Seeplex/ScreenTape detection platform will be introduced to clinical and [...]
Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim - Laupheim, Germany, Mai 21, 2008 - Rentschler Biotechnologie and Boehringer Ingelheim, both leading companies in biopharmaceutical development and production, have signed a preferred partnership agreement. The cooperation will enable Rentschler Biotechnologie’s clients to gain access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production facilities in Biberach, Germany and vice versa, [...]
GTCbio’s 3rd Imaging in Pre-clinical & Clinical Drug Development Conference. March 17-18, 2008 - San Diego, CA - The obstacles to successful drug discovery and development are numerous and well appreciated. In discovery, from target identification through lead optimization and validation, and in development, from first-in-man studies through large registration trials, inefficiencies and uncertainties complicate even well-funded efforts by sophisticated and industrious scientists and clinicians. Despite huge outlays by the worldwide pharmaceutical research [...]
Biological Drugs Spurring an Evolution in Injectable Drug Delivery - (Amherst, NH) - The success of recombinant protein drugs such as Enbrel, Remicade, and Herceptin in treating refractory conditions is fueling the search for protein and peptide-based therapeutic agents in oncology, inflammation and a host of other disease classes. Led by the proliferation of antibody-based drug candidates, biological drugs as a class continue to outpace [...]
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity - Patients with FDA-defined Valvulopathy Permitted to Enroll in 2nd and 3rd Pivotal Trials - Echocardiogram Screening Requirement Eliminated
SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ — Arena Pharmaceuticals, Inc. today announced the initiation of patient screening in the second and third Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for [...]
7th Annual Protein Kinases Congress 10-12 March 2008 in Crowne Plaza Berlin City Centre, Berlin, Germany - Innovating kinase inhibitor development is the key to successful clinical development. At Informa Life Sciences 7th Annual Protein Kinases Congress hear the latest thinking and strategies towards creating a selective inhibitor. Learn about new targets, industry trends in structure-based drug design, clinical case-studies and discuss the issue of cardiotoxicity.
For more information visit: http://www.iir-events.com/IIR-Conf/page.aspx?id=9547
New Clinical Trial Code break System ‘Safecode’ - ‘Safecode’ is a new system for clinical trials represents a significant enhancement over traditional CODEBREAK product identification
methods.
Our system allows confidential information to be printed using industry standard inkjet technology.
The printed information is illegible unless a tamper evident strip is removed. This ensures that any effort to compromise the security of data is immediately apparent.
http://www.acs-labels.co.uk/Safecode.htm
BIOSERVE and DNAPRINT(R) GENOMICS FORM STRATEGIC ALLIANCE TO PROVIDE CLINICAL PATIENT SAMPLES TAGGED WITH GENETIC ANCESTRY DATA - BioServe’s fully annotated clinical samples across many diseases to be tagged with ancestry information using DNAPrint’s genetic ancestry tests
BELTSVILLE, MD., Oct. 9, 2007 – BioServe today announced the formation of strategic alliance with DNAPrint® Genomics, Inc. (OTCBB: DNAG) to provide biomedical researchers with clinical DNA samples that for the first time will include genetic ancestry [...]
New compounds promising candidates for neurodegenerative disease drug development - Scientists have developed a novel strategy for tackling neurodegenerative diseases such as Huntington’s disease: encouraging an individual’s own cells to “eat” the malformed proteins that lead to the disease.
Huntington’s disease is one of a number of degenerative diseases marked by clumps of malformed protein in brain cells. Symptoms include abnormal movements, psychiatric disturbances like depression [...]
Links
|
|
